Overall local/injection site adverse events at 15‐day · 9‐ to 26‐year‐old females and males
Nonavalent HPV vaccine leads to higher overall local/injection site adverse events at 15‐day compared with quadrivalent HPV vaccine (high certainty).
1 finding from 1 review
Number of children with mild‐to‐severe adverse events · children with egg allergy
Oral and sublingual immunotherapy may leads to higher number of children with mild‐to‐severe adverse events compared with no therapy (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events leading to treatment discontinuation ( · adults and adolescents with pleural TB
The intervention may leads to higher adverse events leading to treatment discontinuation ( (low certainty).
1 finding from 1 review
Serious adverse events (During ED/hospital admission) · adults and children with acute exacerbation of asthma
1 finding from 1 review
Serious adverse events (During ED/hospital admission) · adults and children with acute exacerbation of asthma
1 finding from 1 review
Intervention not reported
Adverse events (number of adverse events/person/year) · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
The intervention showed no clear difference in adverse events (number of adverse events/person/year) (low certainty).
1 finding from 1 review
Specific adverse events · women with PMS
It is very uncertain whether oestrogen in combination with progestogen (sequential or continuous) changes specific adverse events over 2 to 4 menstrual cycles1 compared with placebo (very low certainty).
1 finding from 1 review
no estimate extracted
206 participants
Very low
Incidence of adverse events within 30 days of surgery · aged 18 years and older undergoing elective surgery at any surgical site
1 finding from 1 review
Incidence of adverse events within 30 days of surgery · aged 18 years and older undergoing elective surgery at any surgical site
1 finding from 1 review
Adverse events (not including serious adverse events): number of participants · patients with chronic obstructive pulmonary disease
Umeclidinium bromide showed no clear difference in adverse events (not including serious adverse events) compared with placebo (moderate certainty).
1 finding from 1 review
Adverse serious events (any) (number of participants) · patients with opioid dependence
It is very uncertain whether supervised dosing with a long‐acting medication changes adverse serious events (any) (number of participants) compared with unsupervised consumption (very low certainty).
1 finding from 1 review
Nausea and vomiting · patients with rapid emergence from anaesthesia after undergoing brain tumour surgery
Propofol may leads to lower adverse event ‐ nausea and vomiting, number of events compared with sevoflurane (low certainty).
1 finding from 1 review
Intervention not reported
Incidence of adverse events within 30 days of surgery · adults aged ≥ 18 years undergoing elective surgery at any surgical site
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawal due to serious adverse events Not reported · patients with rheumatoid arthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawal due to serious adverse events Not reported · patients with rheumatoid arthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawal due to serious adverse events Not reported · patients with rheumatoid arthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants who withdraw because of an adverse event or any other reason · patients for whom migraine preventive interventions are indicated
SSRIs or SNRIs showed no clear difference in withdrawn (for any reasons and due to adverse events) compared with amitriptyline (low certainty).
1 finding from 1 review
Adverse events: serious adverse events ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events (AEs; adverse drug reaction): asystole · patients with myocardial infarction
It is very uncertain whether lidocaine changes adverse events (AEs; adverse drug reaction): asystole compared with disopyramide (very low certainty).
1 finding from 1 review
Adverse events (AEs; adverse drug reaction): asystole · patients with acute myocardial infarction
It is very uncertain whether lidocaine changes adverse events (AEs; adverse drug reaction): asystole compared with placebo or no intervention (very low certainty).
1 finding from 1 review